![1]()
News
Coronary CT angiography gives superior MI risk prediction
May 8, 2020
Low-attenuation noncalcified plaque burden cuts to the heart of cardiovascular risk prediction.
News
Results from 11 AHA-funded COVID-19 studies expected within months
May 7, 2020
The AHA’s COVID-19 and Its Cardiovascular Impact Rapid Response Grant initiative awards $1.2 million in grants.
News
FDA approves dapagliflozin for low-EF heart failure
May 7, 2020
The approval based on DAPA-HF makes dapagliflozin (Farxiga) the only drug in its class to be indicated for heart failure in the absence of diabetes.
News
New angiotensin studies in COVID-19 give more reassurance
May 6, 2020
A deluge of new data does not suggest harm with ACE inhibitors and angiotensin blockers in COVID-19 rates or outcomes.
News
Multisociety roadmap eyes restarting elective cardiac cases
May 6, 2020
A new consensus document provides guidance on the safe reintroduction of cardiovascular procedures and testing derailed by the COVID-19 pandemic.
News
Diastolic dysfunction is a common risk factor for cognitive decline
May 5, 2020
Proposed mechanisms for cognitive decline in patients with systolic dysfunction include low cardiac output, embolic infarctions, and hypoxic changes, among others.
![1]()
News
Adding mechanical to pharma prophylaxis does not cut DVT incidence
May 4, 2020
Does adding mechanical prophylaxis to pharmacological prophylaxis lower the incidence of deep-vein thrombosis (DVT)?
![1]()
News
Hydroxychloroquine-triggered QTc-interval prolongations mount in COVID-19 patients
May 4, 2020
Two single-center reports further documented the incidence of QTc-interval prolongations in COVID-19 patients treated with hydroxychloroquine.
News
Out-of-hospital cardiac arrests soar during COVID-19 in Italy
May 1, 2020
Four provinces in northern Italy report increases of various magnitudes, ranging from 18% to a stunning 187%.
News
New study of diabetes drug for COVID-19 raises eyebrows
May 1, 2020
Some question the safety of AstraZeneca’s just-launched DARE-19 study testing whether dapagliflozin will reduce adverse outcomes of COVID-19.
